Buprenorphine cuts length of stay nearly in half for infants withdrawing from opioids
Thomas Jefferson University News May 13, 2017
New research published May 4 in the New England Journal of Medicine demonstrated that a more effective treatment can safely cut the duration of neonatal abstinence syndrome (NAS) therapy nearly in half.
ÂThis is a practice–changing advance for treatment of babies with NAS, says the lead author of the study Walter Kraft, MD, Professor and Director, Clinical Research Unit in the Department of Pharmacology and Experimental Therapeutics in the Sidney Kimmel Medical College at Thomas Jefferson University. ÂWe predict that buprenorphine will become the new standard of care for NAS.Â
The current standard of care for infants who experience withdrawal symptoms, or NAS, is treatment with morphine until the symptoms subside. However, because pediatric populations are difficult to study, robust evidence from clinical trials supporting morphine were lacking.
ÂTesting therapeutics in infants has always been challenging. Families are understandably apprehensive about entering their infants into clinical trials, says Kraft. ÂBut it is essential that we study whether these therapies are effective, because infants are not simply smaller versions of adults. Their physiology is unique and we need to continue to build evidence for their treatment. Improving care based on solid evidence was at the heart of this study.Â
The clinical trial was designed with multiple checks and balances to ensure the results were not skewed by the perception of the families or the health care providers. Between October 2011 and May 2016, the investigators enrolled 63 infants in the study and divided them into two treatment groups. Infants with withdrawal symptoms were treated with either morphine or buprenorphine in a blinded fashion so that neither the health care providers nor the families knew which treatment was given after all of the data was collected.
The research team found that the 30 infants treated with morphine required the therapy for an average of 28 days before their withdrawal symptoms were under control and they were fully weaned. Whereas the 33 infants allocated to buprenorphine only required an average of 15 days of the medication. The buprenorphine reduced treatment time by 47 percent.
ÂWe suspect that buprenorphine is more effective because it works a little differently at the opioid receptor. It is also a longer lasting drug than morphine, requiring a dose every eight hours rather than the four required for morphine, says Kraft. The trial found buprenorphine to be as safe as morphine. Though not tested in this study, treatment of infants at home with buprenorphine may eventually be possible due to these favorable characteristics.
"The beauty of our results is that the drug is immediately readily available, unequivocally effective, non–invasive and safe. This could impact standard of care for and the financial cost of neonatal abstinence syndrome," said Michelle E. Ehrlich, MD, from The Icahn School of Medicine at Mount Sinai, who had initiated research on buprenorphine at Jefferson with Dr. Kraft before moving to New York. ÂIn future studies, Dr. Kraft and I hope to research how genetics may inform and influence an infantÂs response to medication.Â
Go to Original
ÂThis is a practice–changing advance for treatment of babies with NAS, says the lead author of the study Walter Kraft, MD, Professor and Director, Clinical Research Unit in the Department of Pharmacology and Experimental Therapeutics in the Sidney Kimmel Medical College at Thomas Jefferson University. ÂWe predict that buprenorphine will become the new standard of care for NAS.Â
The current standard of care for infants who experience withdrawal symptoms, or NAS, is treatment with morphine until the symptoms subside. However, because pediatric populations are difficult to study, robust evidence from clinical trials supporting morphine were lacking.
ÂTesting therapeutics in infants has always been challenging. Families are understandably apprehensive about entering their infants into clinical trials, says Kraft. ÂBut it is essential that we study whether these therapies are effective, because infants are not simply smaller versions of adults. Their physiology is unique and we need to continue to build evidence for their treatment. Improving care based on solid evidence was at the heart of this study.Â
The clinical trial was designed with multiple checks and balances to ensure the results were not skewed by the perception of the families or the health care providers. Between October 2011 and May 2016, the investigators enrolled 63 infants in the study and divided them into two treatment groups. Infants with withdrawal symptoms were treated with either morphine or buprenorphine in a blinded fashion so that neither the health care providers nor the families knew which treatment was given after all of the data was collected.
The research team found that the 30 infants treated with morphine required the therapy for an average of 28 days before their withdrawal symptoms were under control and they were fully weaned. Whereas the 33 infants allocated to buprenorphine only required an average of 15 days of the medication. The buprenorphine reduced treatment time by 47 percent.
ÂWe suspect that buprenorphine is more effective because it works a little differently at the opioid receptor. It is also a longer lasting drug than morphine, requiring a dose every eight hours rather than the four required for morphine, says Kraft. The trial found buprenorphine to be as safe as morphine. Though not tested in this study, treatment of infants at home with buprenorphine may eventually be possible due to these favorable characteristics.
"The beauty of our results is that the drug is immediately readily available, unequivocally effective, non–invasive and safe. This could impact standard of care for and the financial cost of neonatal abstinence syndrome," said Michelle E. Ehrlich, MD, from The Icahn School of Medicine at Mount Sinai, who had initiated research on buprenorphine at Jefferson with Dr. Kraft before moving to New York. ÂIn future studies, Dr. Kraft and I hope to research how genetics may inform and influence an infantÂs response to medication.Â
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries